- Video Center
- Social Media
- Media Contacts
Berlin, Germany, July 26, 2021 – Bayer today announced Prof. Dr. Dominik Ruettinger as the new Head of Research and Early Development for Oncology at its Pharmaceuticals Division, effective October 1, 2021.
“We are pleased to welcome Dominik Ruettinger who is a leader in oncology translational clinical research and therapeutic development and brings extensive experience that will help us to leverage science and innovative solutions to change medical practice and ultimately create superior outcomes for cancer patients,” said Dr. Christian Rommel, Head of Research and Development and Member of the Pharmaceuticals Executive Committee of Bayer AG. “Achieving breakthrough innovation through our pipeline is at the core of our strategy for delivering the transformation of our pharma business.”
Dominik Ruettinger joins Bayer from Roche where he most recently headed Early Clinical and Biomarker Development in Pharma Research and Early Development (pRED). Before he joined Roche in 2011, Dominik Ruettinger was at Micromet Inc. (now Amgen Inc.) where he led all solid tumor development programs and supported the development of Blinatumumab (Blincyto™), eventually resulting in the approval of this first CD19-directed T-cell bispecific in 2014.
Dominik Ruettinger has spent 12 years in academia (Germany and US), is board certified in Surgical Oncology and holds a PhD degree in tumor immunology from the University of Munich, where he also served as principal investigator on multiple Phase I-III clinical oncology trials.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.
Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: @BayerPharma
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center